Mus vs Qatar: The number of people with susceptibility test result for rifampicin
Mus
100
in 2021
Qatar
100
in 2021
Mus rank
1st
Qatar rank
2nd
The number of people with susceptibility test result for rifampicin over time
- Mus
- Qatar
How they compare
Mus currently reports 100 against 100 in Qatar, a difference of 0.
The two have swapped places 2 times across 5 shared years of data; in 2017 it was Qatar ahead.
Mus ranks 1st and Qatar ranks 2nd of 2 regions.
Mus has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Mus | Qatar | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 100 | 83.79 | 16.21 | Mus |
| 2020s | 100 | 100 | 0 | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Mus or Qatar?
- Mus, at 100 against 100 in Qatar as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Mus and Qatar?
- 0, with Mus ahead.
- How many years of comparable data are there for Mus and Qatar?
- 5 years are reported by both, from 2017 to 2021.
- How do Mus and Qatar rank globally for the number of people with susceptibility test result for rifampicin?
- Mus ranks 1st and Qatar ranks 2nd of 2 regions.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.